Vertical Hot Melt Extrusion shows major results in international journal Pharmaceutics

Rondol is proud to announce the publication of its latest scientific research in the journal Pharmaceutics.

The study titled “Vertical Hot-Melt Extrusion: The Next Challenge in Innovation,” confirms the company’s pioneering work in vertical hot-melt extrusion (HME)—its next-generation platform designed to enhance formulation and drug manufacturing.

A Game-Changer for Industry and innovation:

While horizontal hot-melt extrusion has already been widely adopted in the industry, Rondol’s vertical extrusion platform goes even further, bringing a new dimension of low footprint, feeding efficiency, enhanced temperature control and improved material flow using gravity to continuous pharmaceutical manufacturing.

This GMP compliant innovation reduces costs while enabling the production of stable amorphous solid dispersions (ASDs) with enhanced solubility, bioavailability, and batch consistency —especially valuable for poorly soluble or thermosensitive Active Pharmaceutical Ingredients (APIs) and formulations (e.g. Soluplus® or Kollidon® 12 PF (BASF)).

Key results:

In collaboration with the Université de Lorraine and the Institut Jean Lamour (IJL) (CNRS), the study demonstrated how vertical HME:

• Produces homogeneous ASD of acetylsalicylic acid (ASA) (supplied by Seqens)

• Enhances drug dissolution rates and bioavailability compared to crystalline ASA

• Delivers high reproducibility, even at high API loadings (up to 50%)

• Enables nanostructural densification, validated through small-angle X-ray scattering (SAXS)

At Rondol, we are convinced that Vertical Extrusion represents a cleaner, smarter, and more efficient way to formulate challenging drugs. A new tool, perfectly fitted for modern pharmaceutical needs.

Read the full article in Pharmaceutics.